This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trkola, A.
Right arrow Articles by Olson, W. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trkola, A.
Right arrow Articles by Olson, W. C.

 Previous Article  |  Next Article 

Journal of Virology, January 2001, p. 579-588, Vol. 75, No. 2
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.2.579-588.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140

Alexandra Trkola,1,dagger Thomas J. Ketas,2 Kirsten A. Nagashima,2 Lu Zhao,2 Tonie Cilliers,3 Lynn Morris,3 John P. Moore,1,Dagger Paul J. Maddon,2 and William C. Olson2,*

The Aaron Diamond AIDS Research Center, New York,1 and Progenics Pharmaceuticals, Inc., Tarrytown,2 New York, and National Institute for Virology, Johannesburg, South Africa3

Received 14 September 2000/Accepted 13 October 2000

CCR5 serves as a requisite fusion coreceptor for clinically relevant strains of human immunodeficiency virus type 1 (HIV-1) and provides a promising target for antiviral therapy. However, no study to date has examined whether monoclonal antibodies, small molecules, or other nonchemokine agents possess broad-spectrum activity against the major genetic subtypes of HIV-1. PRO 140 (PA14) is an anti-CCR5 monoclonal antibody that potently inhibits HIV-1 entry at concentrations that do not affect CCR5's chemokine receptor activity. In this study, PRO 140 was tested against a panel of primary HIV-1 isolates selected for their genotypic and geographic diversity. In quantitative assays of viral infectivity, PRO 140 was compared with RANTES, a natural CCR5 ligand that can inhibit HIV-1 entry by receptor downregulation as well as receptor blockade. Despite their divergent mechanisms of action and binding epitopes on CCR5, low nanomolar concentrations of both PRO 140 and RANTES inhibited infection of primary peripheral blood mononuclear cells (PBMC) by all CCR5-using (R5) viruses tested. This is consistent with there being a highly restricted pattern of CCR5 usage by R5 viruses. In addition, a panel of 25 subtype C South African R5 viruses were broadly inhibited by PRO 140, RANTES, and TAK-779, although ~30-fold-higher concentrations of the last compound were required. Interestingly, significant inhibition of a dualtropic subtype C virus was also observed. Whereas PRO 140 potently inhibited HIV-1 replication in both PBMC and primary macrophages, RANTES exhibited limited antiviral activity in macrophage cultures. Thus CCR5-targeting agents such as PRO 140 can demonstrate potent and genetic-subtype-independent anti-HIV-1 activity.

* Corresponding author. Mailing address: Progenics Pharmaceuticals, Inc., 777 Old Saw Mill River Rd., Tarrytown, NY 10591. Phone: (914) 789-2800. Fax: (914) 789-2807. E-mail: olson{at}progenics.com.

dagger Present address: Division of Infectious Diseases, Department of Internal Medicine, University Hospital Zurich, U Pol 33, CH-8091 Zurich, Switzerland.

Dagger Present address: Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, N.Y.

Journal of Virology, January 2001, p. 579-588, Vol. 75, No. 2
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.2.579-588.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ji, C., Zhang, J., Dioszegi, M., Chiu, S., Rao, E., deRosier, A., Cammack, N., Brandt, M., Sankuratri, S. (2007). CCR5 Small-Molecule Antagonists and Monoclonal Antibodies Exert Potent Synergistic Antiviral Effects by Cobinding to the Receptor. Mol. Pharmacol. 72: 18-28 [Abstract] [Full Text]  
  • Zhang, J., Rao, E., Dioszegi, M., Kondru, R., DeRosier, A., Chan, E., Schwoerer, S., Cammack, N., Brandt, M., Sankuratri, S., Ji, C. (2007). The Second Extracellular Loop of CCR5 Contains the Dominant Epitopes for Highly Potent Anti-Human Immunodeficiency Virus Monoclonal Antibodies. Antimicrob. Agents Chemother. 51: 1386-1397 [Abstract] [Full Text]  
  • Whitcomb, J. M., Huang, W., Fransen, S., Limoli, K., Toma, J., Wrin, T., Chappey, C., Kiss, L. D. B., Paxinos, E. E., Petropoulos, C. J. (2007). Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism. Antimicrob. Agents Chemother. 51: 566-575 [Abstract] [Full Text]  
  • Yi, L., Fang, J., Isik, N., Chim, J., Jin, T. (2006). HIV gp120-induced Interaction between CD4 and CCR5 Requires Cholesterol-rich Microenvironments Revealed by Live Cell Fluorescence Resonance Energy Transfer Imaging. J. Biol. Chem. 281: 35446-35453 [Abstract] [Full Text]  
  • Aquaro, S., Svicher, V., Schols, D., Pollicita, M., Antinori, A., Balzarini, J., Perno, C. F. (2006). Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J. Leukoc. Biol. 80: 1103-1110 [Abstract] [Full Text]  
  • Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J., Olson, W. C. (2006). Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1.. Antimicrob. Agents Chemother. 50: 3289-3296 [Abstract] [Full Text]  
  • Briz, V., Poveda, E., Soriano, V. (2006). HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57: 619-627 [Abstract] [Full Text]  
  • Baba, M., Takashima, K., Miyake, H., Kanzaki, N., Teshima, K., Wang, X., Shiraishi, M., Iizawa, Y. (2005). TAK-652 Inhibits CCR5-Mediated Human Immunodeficiency Virus Type 1 Infection In Vitro and Has Favorable Pharmacokinetics in Humans. Antimicrob. Agents Chemother. 49: 4584-4591 [Abstract] [Full Text]  
  • Takashima, K., Miyake, H., Kanzaki, N., Tagawa, Y., Wang, X., Sugihara, Y., Iizawa, Y., Baba, M. (2005). Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist. Antimicrob. Agents Chemother. 49: 3474-3482 [Abstract] [Full Text]  
  • Rusert, P., Kuster, H., Joos, B., Misselwitz, B., Gujer, C., Leemann, C., Fischer, M., Stiegler, G., Katinger, H., Olson, W. C., Weber, R., Aceto, L., Gunthard, H. F., Trkola, A. (2005). Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors. J. Virol. 79: 8454-8469 [Abstract] [Full Text]  
  • Khurana, S., Kennedy, M., King, L. R., Golding, H. (2005). Identification of a Linear Peptide Recognized by Monoclonal Antibody 2D7 Capable of Generating CCR5-Specific Antibodies with Human Immunodeficiency Virus-Neutralizing Activity. J. Virol. 79: 6791-6800 [Abstract] [Full Text]  
  • Barassi, C., Soprana, E., Pastori, C., Longhi, R., Buratti, E., Lillo, F., Marenzi, C., Lazzarin, A., Siccardi, A. G., Lopalco, L. (2005). Induction of Murine Mucosal CCR5-Reactive Antibodies as an Anti-Human Immunodeficiency Virus Strategy. J. Virol. 79: 6848-6858 [Abstract] [Full Text]  
  • Bouhlal, H., Latry, V., Requena, M., Aubry, S., Kaveri, S. V., Kazatchkine, M. D., Belec, L., Hocini, H. (2005). Natural Antibodies to CCR5 from Breast Milk Block Infection of Macrophages and Dendritic Cells with Primary R5-Tropic HIV-1. J. Immunol. 174: 7202-7209 [Abstract] [Full Text]  
  • Blanco, J., Barretina, J., Clotet, B., Este, J. A. (2004). R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J. Leukoc. Biol. 76: 804-811 [Abstract] [Full Text]  
  • Greenberg, M. L., Cammack, N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54: 333-340 [Abstract] [Full Text]  
  • Pastore, C., Ramos, A., Mosier, D. E. (2004). Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching. J. Virol. 78: 7565-7574 [Abstract] [Full Text]  
  • Chackerian, B., Briglio, L., Albert, P. S., Lowy, D. R., Schiller, J. T. (2004). Induction of Autoantibodies to CCR5 in Macaques and Subsequent Effects upon Challenge with an R5-Tropic Simian/Human Immunodeficiency Virus. J. Virol. 78: 4037-4047 [Abstract] [Full Text]  
  • Jacobson, J. M., Israel, R. J., Lowy, I., Ostrow, N. A., Vassilatos, L. S., Barish, M., Tran, D. N. H., Sullivan, B. M., Ketas, T. J., O'Neill, T. J., Nagashima, K. A., Huang, W., Petropoulos, C. J., Moore, J. P., Maddon, P. J., Olson, W. C. (2004). Treatment of Advanced Human Immunodeficiency Virus Type 1 Disease with the Viral Entry Inhibitor PRO 542. Antimicrob. Agents Chemother. 48: 423-429 [Abstract] [Full Text]  
  • Moore, J. P., Shattock, R. J. (2003). Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?. J Antimicrob Chemother 52: 890-892 [Full Text]  
  • Kilby, J. M., Eron, J. J. (2003). Novel Therapies Based on Mechanisms of HIV-1 Cell Entry. NEJM 348: 2228-2238 [Full Text]  
  • Binley, J. M., Cayanan, C. S., Wiley, C., Schulke, N., Olson, W. C., Burton, D. R. (2003). Redox-Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1 Pseudovirions. J. Virol. 77: 5678-5684 [Abstract] [Full Text]  
  • Cilliers, T., Nhlapo, J., Coetzer, M., Orlovic, D., Ketas, T., Olson, W. C., Moore, J. P., Trkola, A., Morris, L. (2003). The CCR5 and CXCR4 Coreceptors Are Both Used by Human Immunodeficiency Virus Type 1 Primary Isolates from Subtype C. J. Virol. 77: 4449-4456 [Abstract] [Full Text]  
  • Ketas, T. J., Frank, I., Klasse, P. J., Sullivan, B. M., Gardner, J. P., Spenlehauer, C., Nesin, M., Olson, W. C., Moore, J. P., Pope, M. (2003). Human Immunodeficiency Virus Type 1 Attachment, Coreceptor, and Fusion Inhibitors Are Active against both Direct and trans Infection of Primary Cells. J. Virol. 77: 2762-2767 [Abstract] [Full Text]  
  • Marechal, V., Prevost, M.-C., Petit, C., Perret, E., Heard, J.-M., Schwartz, O. (2001). Human Immunodeficiency Virus Type 1 Entry into Macrophages Mediated by Macropinocytosis. J. Virol. 75: 11166-11177 [Abstract] [Full Text]  
  • Hogan, C. M., Hammer, S. M. (2001). Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics. ANN INTERN MED 134: 978-996 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»